Biochemistry · Skim version

Lipid Synthesis: Building Cholesterol from Acetyl-CoA

About 1 min to skim · 4 figures · Rewritten on

Read the full lesson → Skim the whole course →

The guiding idea

Skin cells from children whose blood is flooded with cholesterol keep making more of it. Why would a cell bathed in cholesterol keep building it?

Cells get cholesterol two ways, by building it from two-carbon acetyl-CoA and by taking up LDL through the LDL receptor, and one gauge, the cholesterol level in the ER membrane read by SCAP, sets both through SREBP-2.

From the film

  • A liver cell gets cholesterol by making it or importing LDL.
  • In liver cells, ER cholesterol controls both supply lines through SCAP and SREBP-2.
  • Statins block HMG-CoA reductase and indirectly raise LDL receptors.
  • In most familial hypercholesterolemia, too few working LDL receptors slow clearance.
  1. The spine: condense, assemble, cyclize

  2. Where the throttle sits

    AI-generated illustration: the mevalonate pathway drawn as a pipe. Acetyl-CoA flows to HMG-CoA, through a gold valve labelled HMG-CoA reductase, to mevalonate, IPP and farnesyl-PP, where side branches lead to CoQ10, dolichol, prenyl anchors and vitamin K; the main line passes a second valve, squalene synthase, to squalene, lanosterol and cholesterol. An inset shows that a statin greys out every branch, while a squalene synthase inhibitor greys out only the sterol branch.
    Mevalonate feeds a shared trunk. HMG-CoA reductase, the main throttle, sits at the top, so a statin cuts the whole isoprenoid supply, CoQ10 and the prenyl anchors included; squalene synthase commits carbon to sterols only, so blocking it spares the side branches. AI-generated illustration
  3. How LDL gets in

    AI-generated illustration: a left-to-right schematic of LDL being taken into a cell, with an LDL bead bound to receptors at a clathrin-coated pit, an endosome where the receptors recycle to the surface, and a lysosome where the LDL releases free cholesterol, plus an inset where PCSK9 sends a receptor to the lysosome.
    The LDL receptor reads ApoB-100, the pit pinches off, the receptor recycles and the LDL goes on to the lysosome; PCSK9 sends the receptor to the lysosome instead, so fewer receptors return to the surface. AI-generated illustration
  4. One gauge, two supply lines

    AI-generated illustration: one liver cell drawn twice. On the left, with ER cholesterol low, SCAP carries SREBP-2 from the ER to the Golgi, a cut piece of SREBP-2 enters the nucleus, and the cell makes many HMG-CoA reductase enzymes on the ER and many LDL receptors at the surface. On the right, with ER cholesterol high, cholesterol sits on SCAP, Insig grips SCAP, the pair stays in the ER, and the cell has few reductase enzymes and few LDL receptors.
    One gauge sets both supply lines. When ER cholesterol is low, SCAP escorts SREBP-2 to the Golgi, where it is cut and freed to turn on the reductase and the LDL-receptor genes together; when it is high, cholesterol binds SCAP, Insig grips SCAP, and both lines are turned down. Insig and cholesterol act on SCAP, not on SREBP-2. AI-generated illustration
  5. Same gauge, more drugs

  6. What cholesterol becomes

  7. Going deeper

    AI-generated illustration: two side-by-side panels of Lipin 1 at the ER membrane. Left, less phosphorylated Lipin 1 sits on the membrane next to its substrate phosphatidate, with a thick gold arrow to more diacylglycerol. Right, more phosphorylated Lipin 1 with phosphate flags floats in the cytosol, with a thin dashed arrow to less diacylglycerol.
    Lipin 1 localization changes its access to substrate at the ER membrane: less phosphorylated Lipin 1 associates more with the membrane and makes more diacylglycerol; more heavily phosphorylated Lipin 1 is mostly cytosolic and makes less. The diacylglycerol supplies both storage fat and membrane phospholipids. AI-generated illustration

Read the full lesson → Skim the whole course →